Navigation Links
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Date:12/2/2008

SKOKIE, Ill., Dec. 2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints. HZT-501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (gastric and/or duodenal) ulcers in patients with mild-to-moderate pain when compared to ibuprofen alone.

NSAIDs such as ibuprofen are among the most widely used drugs in the world. However, NSAIDs are associated with a range of adverse side effects, which primarily affect the gastrointestinal (GI) tract. Up to 30 percent of patients taking NSAIDs experience gastrointestinal ulcers and a greater percent suffer from upper GI symptoms (i.e., dyspepsia, heartburn).

"NSAIDs, while highly effective in treating pain and inflammation, often lead to serious safety concerns, including significant gastrointestinal damage," said Timothy P. Walbert, president and chief executive officer, Horizon Therapeutics. "We are committed to bringing this much needed treatment to physicians and patients as quickly as possible and plan on submitting these strong HZT-501 Phase 3 results to U.S. and European regulatory authorities in 2009."

REDUCE-1 and REDUCE-2 Trial Design and Results

The Registration Endoscopic Study to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Study (REDUCE-1 and REDUCE-2) were two randomized, double-blind, controlled trials that enrolled more than 1,500 patients in the United States. The primary efficacy objective of REDUCE-1 was to evaluate HZT-501 in reducing the proportion of patients who develop endoscopically diagnosed gastric ulcers during the 24-week treatment pe
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
2. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
5. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
6. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
11. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 /PRNewswire-iReach/ -- "Spain Aesthetic Lasers ... key market data on the Spain Aesthetic Lasers ... in millions of US dollars, volume (in units) ... segments Invasive Body Contouring Devices (Laser-Assisted Liposuction (LAL) ... (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) Devices and Power ...
(Date:9/15/2014)... Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem all ... its 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, ... and has mailed an irrevocable notice of redemption for ... copy of the irrevocable notice of redemption with respect ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical Response, ... services, has been selected by Inc. Magazine as ... America. Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... list identifies successful, privately-held companies with the largest ... Response, one of only two ambulance companies to ...
Breaking Medicine Technology:Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3
(Date:9/16/2014)... is the event of the year for the latest ... of the Acute Cardiovascular Care Association (ACCA) of the ... October in Geneva, Switzerland. , Monday 16 September ... the specialty of cardiology dealing with acute problems in ... and acute heart failure. The scientific programme is available ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 According ... Market Research "Latin America Home Healthcare Market (By ... Healthcare Devices, Mobility Assist Devices and Medical Supplies; ... Infusion Therapy and Unskilled Home Healthcare Services) - ... 2014 - 2020" the Latin American Home Healthcare ...
(Date:9/16/2014)... VA (PRWEB) September 16, 2014 Norfolk, ... of delectable gluten-free and allergy friendly desserts, announced today ... for Breast Cancer Awareness Month this October. In support ... eliminating cancer, Lucy’s® will provide a charitable donation in ... one of the most common cancers among women in ...
(Date:9/16/2014)... HealthDay Reporter , MONDAY, Sept. 15, ... face a higher risk of developing an aggressive type of ... suggests. But, the study authors noted that it,s not ... should be concerned. Their study only found an association between ... prove cause and effect. "It is conceivable that, in ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Current students ... the Capstone Event in Yelm, Washington, Oct. 20-26 to ... the year and caps off the remarkable “Masters of ... world in Switzerland, Italy, Australia, South Korea, Mexico, and ... half price for children ages 6-19 and for seniors ...
Breaking Medicine News(10 mins):Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 2Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 2Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 3Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 3Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2
... extensively drug-resistant tuberculosis (XDR TB) in the United States, ... and difficult-to-treat disease between 1993 and 2006, and 77 ... The study appears in the August 15 issue of ... California reports almost 3,000 cases of tuberculosis annually, the ...
... benefits are weighed , , WEDNESDAY, Aug. 13 (HealthDay ... suggests. , Would-be participants in an extramarital affair tend ... researchers from the University of New Hampshire (UNH) and ... the decision differ slightly between men and women, said ...
... Network Growing, BUFFALO, N.Y., Aug. 13 ... national, electronic healthcare network,and has announced the ... healthcare providers., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NYW083LOGO ... Medina Memorial Health Care,System, and MedFirst Urgent ...
... and Two Rivers among Thomson ... MILWAUKEE, Aug. 13 Three Aurora Health Care facilities,are ... having,demonstrated the fastest, most consistent improvement over five consecutive,years., ... Medical Center of,Green Bay were ranked in the Thomson ...
... a,lazy Sunday with a great meal and relaxing spa treatments. Voda ... Sunday, from 12pm - 4pm, Voda Spa offers the taste and ... Brunch Massage $140 Brunch Scrub ... Choose from a selection of delicious dishes from our restaurant. All,brunches ...
... LAKE OSWEGO, Ore., Aug. 13 West Coast ... of LifeWorks Northwest, a,leading non-profit, community-based mental health ... pledge and a corporate gift. The donation,will sponsor ... Children and Youth Recreation Fund., Additionally, West ...
Cached Medicine News:Health News:Extensively drug-resistant tuberculosis found in California 2Health News:Men and Women Calculate Cost of Affairs 2Health News:Wolfson's HealthTransaction Network(R) Signs Four New Hospital Systems 2Health News:Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey 2Health News:Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey 3Health News:West Coast Bank Sponsors LifeWorks Northwest Programs for Children in Low-Income Housing Communities 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: